ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance

AI Briefing

• – ImmunityBio responds to FDA concerns over podcast and un aired television ad.
• – Company submits comprehensive response to Office of Prescription Drug Promotion.
• – ImmunityBio reaffirms commitment to advertising compliance.